Search Results 1581-1590 of 17508 for Absence

  1. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

    Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of ...

  2. Publications - Sarah E. Berini, M.D. - Mayo Clinic

    Elimination of spurious absent sweat response in QSWEAT recordings. Auton Neurosci. 2019 Dec; 222:102589 Epub 2019 Oct 23. View PubMed; Radwan Y, Berini S ...

  3. A Study to Evaluate Infigratinib to Treat Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302) - Mayo Clinic

    1) or negative biopsy within 28 days before randomization to confirm absence of disease at baseline. If have had AEs associated with prior surgery or ...

  4. Clinical trials - Oncology (Medical)

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  5. Cardiovascular Medicine - Clinical trials

    All offspring will undergo postnatal genetic testing for the parental mutation as the gold standard for diagnosing the presence or absence of LQTS. Study of ...

  6. A Study of MT-5111 in HER2-positive Solid Tumors - Mayo Clinic

    Subjects with no previously reported results are eligible in the absence of history of HBV/HCV/HIV. Investigators will test per their discretion;; Subjects ...

  7. Clinical trials - Oncology (Medical)

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  8. Hematology - Clinical trials

    The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); in the absence of exceeding the MTD of ...

  9. Publications - Stephen L. Kopecky, M.D. - Mayo Clinic

    Usefulness of QRS duration in the absence of bundle branch block as an early predictor of survival in non-ST elevation acute myocardial infarction. Am J ...

  10. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

    ... absence of other renal cell carcinoma subtype or urothelial carcinoma);; Bone only urothelial carcinoma or other non-prostate GU tumor;; Urethra carcinoma ...